Slow acting medications for progressive and painful knee osteoarthritis. How do we assess the benefit to risk of these potentially novel therapies?
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-03-01
|
| Series: | Osteoarthritis and Cartilage Open |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2665913124001134 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850239816930689024 |
|---|---|
| author | Nancy E. Lane Lee S. Simon Jeyanesh Tambiah |
| author_facet | Nancy E. Lane Lee S. Simon Jeyanesh Tambiah |
| author_sort | Nancy E. Lane |
| collection | DOAJ |
| format | Article |
| id | doaj-art-227c25b4eac342f2b3d497b6aeb6c193 |
| institution | OA Journals |
| issn | 2665-9131 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Osteoarthritis and Cartilage Open |
| spelling | doaj-art-227c25b4eac342f2b3d497b6aeb6c1932025-08-20T02:01:03ZengElsevierOsteoarthritis and Cartilage Open2665-91312025-03-017110054610.1016/j.ocarto.2024.100546Slow acting medications for progressive and painful knee osteoarthritis. How do we assess the benefit to risk of these potentially novel therapies?Nancy E. Lane0Lee S. Simon1Jeyanesh Tambiah2Corresponding author. Division of Rheumatology and Clinical Immunology, Department of Medicine, U.C. Davis Health, USA.; Department of Medicine, U.C. Davis Health, Sacramento, CA, 95817, USASDG, LLC, One Mifflin Place, Suite 400, Cambridge, MA, 02138, USABiosplice Therapeutics, 9360 Towne Center Dr., San Diego, CA, 92121, USAhttp://www.sciencedirect.com/science/article/pii/S2665913124001134 |
| spellingShingle | Nancy E. Lane Lee S. Simon Jeyanesh Tambiah Slow acting medications for progressive and painful knee osteoarthritis. How do we assess the benefit to risk of these potentially novel therapies? Osteoarthritis and Cartilage Open |
| title | Slow acting medications for progressive and painful knee osteoarthritis. How do we assess the benefit to risk of these potentially novel therapies? |
| title_full | Slow acting medications for progressive and painful knee osteoarthritis. How do we assess the benefit to risk of these potentially novel therapies? |
| title_fullStr | Slow acting medications for progressive and painful knee osteoarthritis. How do we assess the benefit to risk of these potentially novel therapies? |
| title_full_unstemmed | Slow acting medications for progressive and painful knee osteoarthritis. How do we assess the benefit to risk of these potentially novel therapies? |
| title_short | Slow acting medications for progressive and painful knee osteoarthritis. How do we assess the benefit to risk of these potentially novel therapies? |
| title_sort | slow acting medications for progressive and painful knee osteoarthritis how do we assess the benefit to risk of these potentially novel therapies |
| url | http://www.sciencedirect.com/science/article/pii/S2665913124001134 |
| work_keys_str_mv | AT nancyelane slowactingmedicationsforprogressiveandpainfulkneeosteoarthritishowdoweassessthebenefittoriskofthesepotentiallynoveltherapies AT leessimon slowactingmedicationsforprogressiveandpainfulkneeosteoarthritishowdoweassessthebenefittoriskofthesepotentiallynoveltherapies AT jeyaneshtambiah slowactingmedicationsforprogressiveandpainfulkneeosteoarthritishowdoweassessthebenefittoriskofthesepotentiallynoveltherapies |